| Symbol | CLDWW |
|---|---|
| Name | CALIDI BIOTHERAPEUTICS INC. |
| Sector | UNDEFINED |
| Region | North America |
| Industry | - |
| Address | 92121 United States CA 4475 Executive Dr. Suite 200 |
| Telephone | (858)794-9600 |
| Fax | — |
| — | |
| Website | https://www.calidibio.com/ |
| Incorporation | US |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | 12/31 |
| Public Since | — |
| Exchanges | OTC |
| Auditor | BDO USA, LLP; |
| Audit Status | AUDITED |
| Reporting Status | U.S. Reporting: SEC Reporting |
| CIK | 0001855485 |
| Description | Calidi Biotherapeutics is a clinical-stage immuno-oncology company with proprietary technology designed to arm the immune system to fight cancer. Calidis novel stem cell-based platforms are utilizing potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in multiple oncology indications, including high-grade gliomas and solid tumors. Calidis off-the-shelf, universal cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses leading to enhanced efficacy and improved patient safety. This dual approach can potentially treat, or even prevent, metastatic disease. Additional info from OTC: |
CALIDI BIOTHERPUTICS WTS (CLDWW) was added to the list of traded instruments on Pink Current exchange
Read more